Page 768 - Basic _ Clinical Pharmacology ( PDFDrive )
P. 768

754     SECTION VII  Endocrine Drugs


                        TABLE 41–6  Some insulin preparations available in the United States. 1

                         Preparation                                    Species Source     Concentration
                         Short-acting insulins                                              
                           Insulin lispro (Humalog, Lilly)              Human analog       U100, U200
                           Insulin aspart (Novolog, Novo Nordisk)       Human analog       U100
                           Insulin glulisine (Apidra, Sanofi Aventis)   Human analog       U100
                           Regular insulin (Humulin R, Lilly; Novolin R, Novo Nordisk)  Human  U100, U500
                           Regular insulin inhaled (MannKind)           Human              —
                         Long-acting insulins                                               
                           NPH insulin (Humulin N, Lilly, Novolin N, Novo Nordisk)  Human  U100
                           Insulin glargine (Lantus, Toujeo, Sanofi Aventis, Basaglar, Lilly)  Human analog  U100, U300
                           Insulin detemir (Levemir, Novo Nordisk)      Human analog       U100
                           Insulin degludec (Tresiba, Novo Nordisk)     Human analog       U100, U200
                         Premixed insulins                                                  
                            70 NPH/30 regular (Novolin, Novo Nordisk; Humulin, Lilly)  Human  U100
                           75/25 NPL, Lispro (Humalog mix 75/25, Lilly)  Human analog      U100
                           50/50 NPL, Lispro (Humalog mix 50/50, Lilly)  Human analog      U100
                           70/30 NPA, Aspart (Novolog mix 70/30, Novo Nordisk)  Human analog  U100
                           70/30 Degludec/Aspart (Ryzodeg, Novo Nordisk)  Human analog     U100
                        All insulins are now made by recombinant technology; they should be refrigerated and brought to room temperature just before injection.
                        NPA, neutral protamine aspart; NPL, neutral protamine lispro.



                 The physician should then carefully note dosages in both units   great convenience by patients with diabetes who object to wait-
                 and volume to avoid overdosage. The disposable pen avoids this   ing as long as 45 minutes after injecting regular human insulin
                 conversion issue and dispenses the regular U500 insulin in 5-unit   before they can begin their meal, patients must be taught to ingest
                 increments.                                         adequate absorbable carbohydrate early in the meal to avoid hypo-
                   Intravenous infusions of regular insulin are particularly useful   glycemia during the meal. The analogs also have lowest variability
                 in the treatment of diabetic ketoacidosis and during the periopera-  of absorption: approximately 5%. This compares with 25% for
                 tive management of insulin-requiring diabetics.     regular insulin. Another desirable feature of rapidly acting insulin
                                                                     analogs is that their duration of action remains at about 4 hours
                 2.  Rapidly  acting  insulin  analogs—Insulin lispro (Huma-  for most commonly used dosages.  This contrasts with regular
                 log) is an insulin analog in which the proline at position B28 is   insulin, whose duration of action is significantly prolonged when
                 reversed with the lysine at B29. Insulin aspart (Novolog) is a single   larger doses are used.
                 substitution of proline by aspartic acid at position B28. Insulin   The rapidly acting analogs are commonly used in insulin
                 glulisine (Apidra) differs from human insulin in that the amino   pumps. In a double-blind crossover study comparing insulin lis-
                 acid asparagine at position B3 is replaced by lysine and the lysine   pro with regular insulin in insulin pumps, persons using insulin
                 in position B29 by glutamic acid. When injected subcutaneously,   lispro had lower HbA 1c  values and improved postprandial glucose
                 these three analogs quickly dissociate into monomers and are   control with the same frequency of hypoglycemia. However, the
                 absorbed very rapidly, reaching peak serum values in as little as   concern remains that in the event of pump failure, users of the
                 1 hour. The amino acid changes in these analogs do not interfere   rapidly acting insulin analogs will have more rapid onset of hyper-
                 with their binding to the insulin receptor, with the circulating   glycemia and ketosis.
                 half-life, or with their immunogenicity, which are all identical to   While insulin aspart has been approved for intravenous
                 those of human regular insulin.                     use (eg, in hyperglycemic emergencies), there is no advantage
                   Clinical trials have demonstrated that the optimal times   in using insulin aspart over regular insulin by this route. A
                 of  preprandial  subcutaneous  injection  of  comparable  doses  of   U200 concentration of insulin lispro is available in a disposable
                 the  rapid-acting  insulin  analogs  and  of  regular  human insulin   prefilled pen. The only advantage of the U200 over the U100
                 are  15  minutes  and  45  minutes  before  the  meal,  respectively.   insulin lispro preparation is that it delivers the same dose in half
                 Although the more rapid onset of action has been welcomed as a   the volume.
   763   764   765   766   767   768   769   770   771   772   773